Regulation And Legal
Tarsus Shares Fall 8% After Short Report
Tarsus Pharmaceuticals' stock slid about 8% midday Wednesday following Culper Research’s disclosure of a short position in the company.
Culper alleges XDEMVY growth relies on Medicare copay subsidies
